Kyverna's one-year SPS data will test if 46% T25FW gain at 16 weeks holds up
KYSA-8 already hit its primary endpoint with a 46% median walk-speed improvement at Week 16; the H2 2026 update tests whether that effect persists through one year as Kyverna files a rolling BLA.
Executive Summary
- KYSA-8 already reported its primary analysis in April 2026: a median 46% improvement in Timed 25-Foot Walk at Week 16, statistically significant at p=0.0003, with all patients off chronic SPS immunotherapies. This durability follow-up builds on a result that has already happened, not a fresh binary readout.
- The registered ClinicalTrials.gov primary endpoint text still reads as a safety measure, while Kyverna's public disclosures cite T25FW as the efficacy endpoint underpinning the BLA; the model's protocol counters flag this as an endpoint-registry mismatch, which weakens how cleanly the 98.5% endpoint-met probability maps onto a single, stable endpoint definition.
- Kyverna has already secured a positive pre-BLA meeting, FDA agreement that the single-arm design can support submission, and RMAT plus Orphan Drug designations; the company began a rolling BLA submission and expects to complete it in Q4 2026 under priority review, so this readout adds to that filing rather than gating it.
- The trial enrolls 25 patients with no comparator arm, and durability claims lean in part on the earliest two patients treated under a prior investigator-initiated protocol; this caps how decision-grade the one-year update can be even if the topline direction holds.
- No other CD19-directed therapy is in development for stiff person syndrome, so this program stands alone in its indication even as 231 other CD19-directed trials proceed in adjacent autoimmune and oncology settings, meaning the readthrough is to CAR-T durability broadly, not to a head-to-head rival.
What already happened
The primary efficacy question in this program has already been answered once. Kyverna presented KYSA-8's primary analysis in a late-breaking oral session at the American Academy of Neurology annual meeting on April 21, 2026, reporting a median 46% improvement in the Timed 25-Foot Walk test at 16 weeks, statistically significant at p=0.0003 Press ReleasePress ReleaseMay 12, 2026. All six pre-specified secondary endpoints also met significance at p<0.0001, and the company reported that 100% of patients remained free of chronic immunotherapies for SPS through last follow-up Press ReleasePress ReleaseMay 12, 2026. Safety was described as consistent with known CAR-T profiles, with no high-grade cytokine release syndrome or neurotoxicity reported Press ReleasePress ReleaseMay 12, 2026.
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the H2 update adds
The catalyst under discussion is not that primary result. It is the one-year follow-up data Kyverna plans to release in the second half of 2026, layered on top of an already-positive 16-week readout Press ReleasePress ReleaseMay 12, 2026. CEO Warner Biddle framed the broader regulatory context in the company's own words: "As the first company to submit a BLA for an autoimmune CAR T therapy, gaining alignment with the FDA on a single-arm trial and a clear path to submission for miv-cel is a milestone for not only Kyverna but also the field" Press ReleasePress ReleaseMay 12, 2026. The one-year data will test whether the Week 16 effect holds, not whether it exists.
An unresolved endpoint definition
One detail complicates a clean read of the model's confidence. The ClinicalTrials.gov registry for NCT06588491 still lists the primary endpoint as an evaluation of KYV-101's safety, while Kyverna's public disclosures describe T25FW as the efficacy endpoint driving the BLA package NCT06588491+1KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person SyndromeNCT06588491Press ReleaseMay 12, 2026. The dossier's protocol counters flag this as an endpoint-registry mismatch, and the model's clinical-significance and endpoint-met probabilities were generated against that unsettled endpoint definition [AXL-MODEL]. That mismatch, combined with a wide uncertainty band and a low confidence label on the model output, means the 98.5% endpoint-met read should be treated as a base-rate expectation shaped heavily by endpoint-type and phase historical success rates, not as direct evidence the durability data will replicate [AXL-MODEL].
Regulatory momentum already built
None of this changes the fact that Kyverna's regulatory footing looks more secure than the trial's small size might suggest. The company holds RMAT designation, first granted in July 2024 and reaffirmed in December 2025, and Orphan Drug Designation granted in November 2024 and reaffirmed the same month Press ReleasePress ReleaseMay 12, 2026. Following a positive pre-BLA meeting, FDA agreed the single-arm, 25-patient KYSA-8 trial can support a BLA submission, and Kyverna has begun a rolling submission it expects to complete in the fourth quarter of 2026 under priority review Press ReleasePress ReleaseMay 12, 2026. The one-year data add to that package; they do not gate it.
A trial without a rival
No other CD19-directed therapy is developed for stiff person syndrome, so KYV-101 has no direct comparator in its own indication NCT06588491KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person SyndromeNCT06588491. The readthrough instead runs across CD19 CAR-T biology more broadly: 231 trials share this mechanism [AXL-MODEL], including Novartis's rapcabtagene autoleucel in multiple sclerosis and Cabaletta Bio's CABA-201 in lupus, both testing whether the same target and modality produce durable remission in autoimmune disease outside oncology NCT06588491KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person SyndromeNCT06588491. A one-year durability signal showing the Week 16 effect holds would support that broader CD19 CAR-T autoimmune thesis even though it settles nothing about a head-to-head rival.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.